Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
First interim analysis of OTILIA, a large German non-interventional study evaluating bevacizumab-containing therapy in patients with ovarian cancer.

Mustea, A., Mahner, S., Oskay-Oezcelik, G., Wimberger, P., Jungberg, S., Reichert, D., Forstbauer, H., Keller, M., Richter, R., Frank, M., Klawitter, S., Kiewitz, C., Müller, M., Sehouli, J., 2015.

ESMO Annual Meeting (Vienna)

Indikation: Ovarialkarzinom, Ovarian Cancer / Veranstaltung: ESMO / Journal: -
OTILIA
2015
Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Meinerz, Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Meinerz, W., 2015.

Annual Meeting ESGO (Society of Gynaecological Oncology) (0919).

Indikation: Other, Ovarialkarzinom, Ovarian Cancer, Sonstige / Veranstaltung: ESGO / Journal: -
OTILIA
2015
Piaza: Non-interventional Study on Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMML (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder).

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Neidig, C., Teichmann, B., Harde, J., Trarbach, T., 2015.

Oncol Res Treat 38 (suppl.5)(P235), 70. doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PIAZA
2015
Do we miss changes in Quality of Life? Data from the LuLife project in patients with non-small cell lung cancer in Germany.

von Verschuer, U., Sandner, R., Däßler, K.-U., Tessen, H.W., Münz, M., Spring, L., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V45), 13. doi:10.1159/000439070

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2015
Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.

Tesch, H., Ulshöfer, T., Vehling-Kaiser, U., Ottillinger, B., Bulenda, D., Turner, M., 2015.

Oncol Res Treat 38, 146–152. doi:10.1159/000381318

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: - / Journal: Oncology Research and Treatment
HEXAFIL
2015
Anti-anemic treatment of cancer patients in German routine practice – data from a prospective cohort study, the Tumor Anemia Registry (TAR).

Steinmetz, T., Schröder, J., Plath, M., Link, H., Vogt, M., Frank, M., Marschner, N., 2015.

Supportive Care in Cancer 23(Suppl. 1), 361. doi:10.1007/s00520-015-2712-y

Abstract
Download

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: MASCC / Journal: Supportive Care in Cancer
TAR
2015
Chemotherapy-induced nausea and vomiting – treatment and patient-reported outcomes in German outpatient cancer centres: Final data from the Emesis-Registry.

Schröder, J., Wiegand, J., Dörfel, S., Jähnich, S., Boller, E., Marschner, N., 2015.

Support Care Cancer 23(Suppl. 1), S139. doi:10.1007/s00520-015-2712-y

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: MASCC / Journal: Supportive Care in Cancer
Emesis-Register
2015
Relevance of neo- or adjuvant pretreatment in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab as first-line treatment – data from the prospective TKK registry.

Schnell, R., Trarbach, T., Broszeit-Luft, S., Musch, R., Wetzel, N., Kopfmann, S., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V395), 114. doi:10.1159/000439070

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2015
Implementation of RAS testing in patients with metastatic colorectal cancer in German outpatient cancer centers – data from the clinical TKK registry.

Schnell, R., Trarbach, T., Broszeit-Luft, S., Musch, R., Frank, M., Kopfmann, S., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V394), 113–114. doi:10.1159/000439070

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2015
Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Mustea, A., Oskay-Oezcelik, G., Wimberger, P., Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Sehouli, J., 2015.

European Journal of Cancer 51 (suppl 3) 548. 10.1016/S0959-8049(16)31520-9

Abstract

Indikation: Other, Sonstige / Veranstaltung: ECCO (ESMO) / Journal: European Journal of Cancer
OTILIA
2015